Yearly Archives: 2018

Professor Algin to get Turkan Saylan Science Award

Professor Oktay Algın has been given Turkan Saylan Science Award by  the Academy of Association for Supporting Contemporary Life. This award is given to the young academics with outstanding achievements. Turkan Saylan is an important character in Turkish Medical History who has helped to fought and overcome leprosy in Turkey. She was an influencial Turkish […]

Read More

MSc Thesis Defense: Sevgi Gokce Kafali

Sevgi Gokce Kafali has successfully defended her MSc thesis on April 17th, 2018. The title of her thesis is “PHASE-CORRECTING DENOISING FOR DIFFUSION MAGNETIC RESONANCE IMAGING.” This work proposes a simultaneous solution to low-SNR and motion-induced phase problems experienced in diffusion MRI, via a novel phase-correcting non-local means (PC-NLM) filter. Sevgi’s first-author paper on this […]

Read More

MS Thesis Defense: BISMILLAH NASIR ASHFAQ

Bismillah Nasir Ashfaq has successfully defended his MS thesis on 29th of March 2018. The title of the thesis is “A GATE MODULATED DIGITALLY CONTROLLED MODIFIED CLASS-E AMPLIFIER FOR ON-COIL APPLICATION IN MRI.” This highly innovative work may have applications beyond MRI. Nasir is returning to his home, Pakistan, to join Fatima. They are expecting […]

Read More

Dr. Oktay Algin won 2018 BAGEP award

Together with Dr. Algin, five Bilkent University faculty (Ozcan Ozturk,Onur Tokel,Ferdi Karadas,Barbaros Cetin,Meral Ugur Cinar) won the award. This award is given to the young faculty members in order to praise their scientific work by the Science Academy. Earlier, Drs. Saritas and Cukur won this award in 2016 and 2017, respectively.  Ergin Atalar of UMRAM […]

Read More

European patent “NANOPARTICLE FORMULATION CONTAINING FARNESYLTHIOSALICYCLIC ACID”

European patent application (WO2015167408)(PCT/TR2014/000248) entitled “NANOPARTICLE FORMULATION CONTAINING FARNESYLTHIOSALICYCLIC ACID” has been concluded positively and the registration decision has been finalized. Farnesylthiosalicylic acid (Salirasib, FT A), a new generation antineoplastic agent, is a specific inhibitor of Ras protein, which presents in high rate in most of malignant tumors.The patentable study is a targeted chemotherapy  to […]

Read More